Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)

被引：0
|
作者：
Ades, Lionel [1 ]
Lebras, Fabien [1 ]
Sebert, Marie [1 ]
Kelaidi, Charikleia [1 ]
Lamy, Thierry [1 ]
Dreyfus, Francois [1 ]
Delaunay, Jacques [1 ]
Visanica, Sorin [1 ]
Turlure, Pascal [1 ]
Guerci, Agnes [1 ]
Cabrol, Marie Paule [1 ]
Banos, Anne [1 ]
Blanc, Michel [1 ]
Vey, Norbert [1 ]
Eclache, Virginie [1 ]
Chevret, Sylvie [1 ]
Fenaux, Pierre [1 ]
机构：
[1] Grp Francophone Myelodysplasies GFM, Bobigny, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：429 / 430
页数：2
相关论文
共 50 条
  • [41] IMPACT OF 5Q BREAKPOINTS ON CLINICAL OUTCOMES IN PATIENTS WITH IPSS LOW-/INT-1-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ISOLATED DEL(5Q) TREATED WITH LENALIDOMIDE IN THE MDS-004 STUDY
    Gohring, G.
    Giagounidis, A.
    List, A.
    Hellstrom-Lindberg, E.
    Sekeres, M.
    Mufti, G.
    Schlegelbergerl, B.
    Morrill, J.
    Wu, C.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2013, 98 : 80 - 80
  • [42] Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial
    Almeida, Antonio
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Goldberg, Stuart L.
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2135 - 2143
  • [43] Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
    Lode, Laurence
    Menard, Audrey
    Flet, Laurent
    Richebourg, Steven
    Loirat, Marion
    Eveillard, Marion
    Le Bris, Yannick
    Godon, Catherine
    Theisen, Olivier
    Gagez, Anne-Laure
    Cartron, Guillaume
    Commes-Maerten, Therese
    Villemagne, Bruno
    Luycx, Odile
    Godmer, Pascal
    Pellat-Deceunynck, Catherine
    Soussi, Thierry
    Bene, Marie C.
    Delaunay, Jacques
    Peterlin, Pierre
    HAEMATOLOGICA, 2018, 103 (04) : E143 - E146
  • [44] Early Lenalidomide Maintenance to Prevent Relapse of High-Risk MDS and AML Patients with Del(5q) Following Allogeneic HCT - Results of the "LENAMAINT" Trial
    Sockel, Katja
    Greiner, Jochen
    Trenschel, Rudolf
    Unzicker, Christian
    Kobbe, Guido
    Finke, Jurgen
    Germing, Ulrich
    Mohr, Brigitte
    Beelen, Dietrich
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Platzbecker, Uwe
    BLOOD, 2011, 118 (21) : 1320 - 1320
  • [45] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan F.
    Selleslag, Dominik
    Mittelman, Moshe
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Li, Jack Shiansong
    Sugrue, Mary M.
    Fenaux, Pierre
    BLOOD CANCER JOURNAL, 2018, 8
  • [46] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Mikkael A. Sekeres
    Arlene S. Swern
    Aristoteles Giagounidis
    Alan F. List
    Dominik Selleslag
    Moshe Mittelman
    Brigitte Schlegelberger
    Gudrun Göhring
    Jack Shiansong Li
    Mary M. Sugrue
    Pierre Fenaux
    Blood Cancer Journal, 8
  • [47] Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial
    Garcia-Manero, Guillermo
    Almeida, Antonio
    Fenaux, Pierre
    Gattermann, Norbert
    Giagounidis, Aristoteles
    Goldberg, Stuart L.
    Ozawa, Keiya
    Weaver, Jerry
    Santini, Valeria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04): : 213 - +
  • [48] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Fenaux, Pierre
    Gatterman, Norbert
    Ozawa, Keiya
    Goldberg, Stuart L.
    Weaver, Jerry
    Sugrue, Mary M.
    BLOOD, 2016, 128 (22)
  • [49] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    Kuendgen, A.
    Lauseker, M.
    List, A. F.
    Fenaux, P.
    Giagounidis, A. A.
    Brandenburg, N. A.
    Backstrom, J.
    Glasmacher, A.
    Hasford, J.
    Germing, U.
    LEUKEMIA, 2013, 27 (05) : 1072 - 1079
  • [50] A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
    Sardnal, V.
    Rouquette, A.
    Kaltenbach, S.
    Bally, C.
    Chesnais, V.
    Leschi, C.
    Ades, L.
    Santini, V.
    Park, S.
    Toma, A.
    Fenaux, P.
    Dreyfus, F.
    Fontenay, M.
    Kosmider, O.
    LEUKEMIA, 2013, 27 (07) : 1610 - 1613
12345